BPC-157 Arginate
BPC-157 Arginine Salt
BPC-157 arginate is BPC-157 made as an arginine salt rather than the usual acetate salt, and is marketed as more stable and better absorbed by mouth. Those claims have not been tested in a published human study. Like other BPC-157, the evidence is from animal and cell studies, and it is not FDA-approved.
Half-life
Not established in humans
Typical Dose
250–500 mcg/day subcutaneous
300/500Route
subcutaneous
Category
healing
Evidence Overview
Strength of evidence across clinical, expert, and experimental lanes.
How BPC-157 Arginate is dosed in practice
Usually taken by subcutaneous (SubQ) injection. Typical range: 250–500 mcg/day subcutaneous. Half-life: Not established in humans. Each card gives the dose, frequency and duration from one evidence lane: Clinical (human trials), Expert (practitioner protocols) or Experimental (early or animal data). These ranges describe what has been studied or used; they are not a prescription.
Work out the units to draw with the reconstitution calculator, how long a vial lasts with the vial duration calculator, and how levels fall between doses with the half-life calculator.
Practitioners who use the arginate form mostly inject it SubQ at the same doses as standard BPC-157. Whether the arginine salt changes stability, absorption or effect in people has not been studied.
- Practitioner protocols
Some users take the arginate form by mouth based on marketing claims of better oral absorption. Reports are uncontrolled and often mixed with injected use, so they cannot show whether oral arginate works.
- Community self-reports
Unlock Full Evidence Sources
Get complete clinical data, expert protocols, and experimental research for BPC-157 Arginate and 90+ other compounds with Pro.
Upgrade to ProSafety & Contraindications
- Active cancer or history of cancer (may promote angiogenesis)
- Pregnancy or breastfeeding
BPC-157 Arginate: common questions
What is BPC-157 Arginate?
BPC-157 arginate is BPC-157 made as an arginine salt rather than the usual acetate salt, and is marketed as more stable and better absorbed by mouth. Those claims have not been tested in a published human study. Like other BPC-157, the evidence is from animal and cell studies, and it is not FDA-approved.
How is BPC-157 Arginate dosed?
BPC-157 Arginate is usually taken by subcutaneous (SubQ) injection. Typical range in DoseCraft's library: 250–500 mcg/day subcutaneous. Expert (practitioner protocols): 250–500 mcg/day subcutaneous; 1–2x daily SubQ injection; 4–12 weeks. Experimental (early or animal data): No established oral dose; Not established; Not established. These ranges describe what has been studied or used; they are not a prescription.
Is BPC-157 Arginate FDA-approved?
No. BPC-157 Arginate is not approved by the FDA for any use in people.
What is the half-life of BPC-157 Arginate?
DoseCraft's library lists a half-life of Not established in humans. Half-life sets how often a compound is dosed and how long it takes to clear: about five half-lives.
Who should not use BPC-157 Arginate?
Listed contraindications: Active cancer or history of cancer (may promote angiogenesis); Pregnancy or breastfeeding.
Free Guides for BPC-157 Arginate
Information is for educational purposes only. Always consult a licensed healthcare provider before starting any peptide regimen.
Page updated . How we grade evidence: methodology.